Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose methotrexate for intraocular lymphoma.

Tracy T Batchelor1, Gina Kolak, Roberto Ciordia

  • 1Massachusetts General Hospital Brain Tumor Center and Neurology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. tbachelor@partners.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 11, 2003
PubMed
Summary

High-dose intravenous methotrexate (MTX) can achieve ocular levels in patients with intraocular lymphoma (IOL). Some patients achieve sustained remission, but lower vitreous levels may impact efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modular and flexible pipeline for intraoperative electrode reconstruction and localization in patients with brain lesions.

Frontiers in neural circuits·2026
Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026
Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026
Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026
Same author

Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: illustrative case.

Journal of neurosurgery. Case lessons·2025
Same author

Oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid.

Taiwan journal of ophthalmology·2025

Area of Science:

  • Ophthalmology
  • Neurology
  • Oncology

Background:

  • Intraocular lymphoma (IOL) often co-occurs with primary central nervous system lymphoma (PCNSL).
  • High-dose methotrexate (MTX) is a potential treatment for these conditions.

Purpose of the Study:

  • To evaluate the efficacy of high-dose intravenous MTX monotherapy for intraocular lymphoma (IOL).
  • To determine if micromolar MTX concentrations are achieved in ocular fluids (aqueous and vitreous humor) after IV administration.

Main Methods:

  • Nine patients with concurrent PCNSL and IOL or isolated IOL received high-dose intravenous MTX (8 g/m²).
  • Ocular fluid MTX concentrations were measured in seven patients with IOL.

Main Results:

Related Experiment Videos

  • Micromolar MTX concentrations were achieved in ocular chambers within 4 hours post-infusion.
  • Seven of nine patients showed an initial response to MTX, with six achieving complete response.
  • Lower MTX concentrations were observed in vitreous humor compared to aqueous humor, and some patients experienced relapse.

    • Conclusions:

    • High-dose intravenous MTX can induce sustained remission in a subset of patients with intraocular lymphoma.
    • Lower vitreous humor MTX concentrations may contribute to treatment resistance or relapse in IOL.